Main Topic: The podcast episode discusses the concept of longevity and its implications on society, economy, and individual lives. The guests, Dr. Andrew Scott and Vijay Poonay, explore how the increasing human lifespan is changing the way we think about health, work, and retirement.
Key Points:
Participants:
Takeaways:
What if the biggest challenge of our time isn’t living longer, but living better?
In this episode, we’re tackling one of humanity’s greatest accomplishments—and perhaps its most overlooked challenge: longevity. As more people live past 100, our systems—healthcare, finance, career planning, and even our cultural perceptions of aging—need a fundamental overhaul.
We’re joined by Dr. Andrew Scott, author of The Longevity Imperative, and Vijay Pande a16z’s Bio & Health general partner, to explore how a shift from “sick care” to “health care” could transform our lives. Together, we discuss the implications of longer lifespans, from the individual choices that can improve our healthspans to the economic and societal shifts required to sustain a healthier, more productive aging society.
Join us as we reimagine the future of aging, where living to 100 can be more than survival—it can be a life well-lived.
Resources:
Find Andrew on X: https://x.com/profandrewscott?lang=en
Find Vijay on X: https://x.com/vijaypande
Learn more about The Longevity Imperative:
https://profandrewjscott.com/the-longevity-imperative/
Stay Updated:
Let us know what you think: https://ratethispodcast.com/a16z
Find a16z on Twitter: https://twitter.com/a16z
Find a16z on LinkedIn: https://www.linkedin.com/company/a16z
Subscribe on your favorite podcast app: https://a16z.simplecast.com/
Follow our host: https://twitter.com/stephsmithio
Please note that the content here is for informational purposes only; should NOT be taken as legal, business, tax, or investment advice or be used to evaluate any investment or security; and is not directed at any investors or potential investors in any a16z fund. a16z and its affiliates may maintain investments in the companies discussed. For more details please see a16z.com/disclosures.
Stay Updated:
Find a16z on X
Find a16z on LinkedIn
Listen to the a16z Podcast on Spotify
Listen to the a16z Podcast on Apple Podcasts
Follow our host: https://twitter.com/eriktorenberg
Please note that the content here is for informational purposes only; should NOT be taken as legal, business, tax, or investment advice or be used to evaluate any investment or security; and is not directed at any investors or potential investors in any a16z fund. a16z and its affiliates may maintain investments in the companies discussed. For more details please see a16z.com/disclosures.
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Host
You're keeping people alive, you're not keeping them healthy.
Andrew Scott
The view that medicine starts with disease is part of the problem because it should start with health.
Host
One in five, one in six Brits are meant to live to 100 according to the government. How do you finance that? Is your 401k set for you to live to 100?
Vijay Pande
People age really, really diversely. And you can be 100 and literally run in 100 meters. You can look at it on YouTube or you can be 50 and in a wheelchair.
Andrew Scott
And instead of this being a crisis, it could be the greatest accomplishment of humanity.
Host
Let's start this episode with a thought experiment. What would you do if you knew you were going to die today? And what would you do if it were impossible to die today? I'd bet that separate from the outcomes, those days would look pretty different. Because probabilities guide our decisions. And that is the premise of today's conversation.
We as humans have extended the aging curve, meaning we are probabilistically living longer. And a whole lot longer. In 1965, the most common age of death was in the first year in the UK. Now that's flipped to 87. And contrary to popular belief, we are still extending lifespan.
So what happens when the calculus is no longer avoiding dying young, but perhaps striving to live extremely old? Plus, what is the life worth? And how does this impact our society, not just in the health system, but the financial sector, career planning, and even direct design?
Joining us to discuss exactly this is Dr. Andrew Scott, author of *The Longevity Imperative*, a book published earlier this year, alongside founding general partner of A16Z Bio & Health, Vijay Pande. Let's get to it.
Disclaimer: The content here is for informational purposes only, should not be taken as legal, business, tax, or investment advice, or be used to evaluate any investment or security, and is not directed at any investors or potential investors in any A16Z fund. Please note that A16Z and its affiliates may also maintain investments in the companies discussed in this podcast. For more details, including a link to our investments, please see A16Z.com slash disclosures.
You could have named the book many things. *The Longevity Imperative* is very specific and very telling of what message you're trying to get across. Let's start there. Why use the term imperative?
Andrew Scott
Partly, I'm a macroeconomist, and I think we've got to face the challenges we have in the world ahead of us. This one just drops off the radar. We talk a lot about AI and climate change and how we have to adapt and adjust. But when it comes to this topic, we tend to talk about an aging society, and we rarely get beyond talking about adult diapers and care homes. I wanted to elevate this topic right up there.
The meaning of imperative is vital importance. And it has a double play, because it's not just vitally important for society because we want to avoid a pensions crisis and a health crisis. It's vitally important for all of us because for the first time ever in human history, the young can expect to become the very old. So how we age is now an incredibly important thing.
Host
Let's quickly double click on that because you actually compare the criticality of longevity to things like AI or climate change, other areas where people widely address as really critical and widely impactful. Why do you position it there relative to those other areas?
Andrew Scott
Because I think it's right up there just as important. We fear getting old. We fear outliving our skills, our health. So that's why there's that longevity imperative. What are you going to do now to age well? But aging is not a sexy word. I know no one who says, "Great, we've got an aging society," which is strange. It's one of the greatest achievements of the 20th century to get global life expectancy above 70. Phenomenal. Fewer children to mourn. Fewer parents snatched away in midlife. More grandparents meeting their grandchildren. And we say, "We've got an aging society." It's a really weird way of framing it.
People switch off with aging, whereas with AI and climate change, it's like, "This is really important. If we don't do this, we're going to have a bad outcome. It's crucial for humanity, crucial for my individual future." All of those statements hold for how you deal with your long life. That's why it's up there. And it's not just me being obsessed with this topic. I can give you very hard data about the welfare gains, but also the economic consequences if we don't adapt. The pensions crisis, the unsustainable health burden. It really is right up there.
Vijay Pande
I don't think anyone other than people who've looked at the economics understands the impact this is having on us, not just as individuals, but as a country. The amount of debt, the amount of expense that comes along with our current healthcare system, especially which is exacerbated with age. It's a very hidden, insidious problem. So I think imperative is spot on.
Host
Absolutely. I'd love to dive into how we need to refashion our economic system, our tax system, the way that people think about their careers, because you talk about all of that, Andrew. But before we get to that, let's take stock of how lifespan and health span have changed, since those are not the same thing. Ground us in how things have changed over the last hundred years or so.
Andrew Scott
In high-income countries over the last 100 years, life expectancy has increased about two or three years every decade. In lower-income countries, even faster. Global life expectancy is now over 73. I think it's worth pausing at that point. A child born today can now expect to live into an eighth decade. And that's based upon no further change, so it's probably a greater number than that because life expectancy is increasing in many countries.
In high-income countries like the UK, the UK government says that 50% of children born today will live to be about 91. That's extraordinary. I start my book with a somewhat dramatic statistic, not about average life expectancy, but about what is the most common age of death. When I was writing the book, I wanted to make it personal and illustrate these demographic trends with my own family. I discovered my own family was stunningly average. They hit nearly every single demographic trend completely.
The most striking one was that when I was born, the most common age of death was children under one in the UK. I was a twin and my twin died in the first few days of life. I thought that was quite rare, but that was the most common age of death. Today, the most common age of death is 87 or 88. In my lifetime, the modal age of death has shifted. Life expectancy is complicated—it's average, mean, and median. But Samuel Beckett, the Irish playwright, says we give birth astride the grave, the light flickers instant and then it goes out. Well, the light's flickering a lot longer now. That's what we've got to prepare for.
Host
You shared so many interesting statistics. I'll share one more that surprised me. Based on 2020 data, you said that a newborn girl in Japan has a 99.6% chance of living to 20, a 99% chance of reaching 40, and a 96% chance of making it to 60. Those are astounding numbers. A few decades ago, in 1965, we were looking at completely different numbers.
Andrew Scott
What's happening is that the survival rate—the probability of a newborn reaching a certain age—is rectangularizing. The chance of a female in Japan reaching 60 is incredibly high now. The chance of reaching 70 is getting higher and higher. That's the real shift. We've lowered infant mortality dramatically. We've made big steps in improving midlife mortality, although the US has some problems there of late. Now all the gains are coming at older ages. Life expectancy is now being driven by falls in mortality at older ages, such that 80% of life expectancy gains in richer countries come from mortality rates coming down after 70. It's just getting further along this rectangularization.
Host
Vijay, I'd love to bring you in here. As you look at both the bio and health side of things, what gives you confidence that this trend might continue?
Vijay Pande
There's a lot of excitement about studying the biology of aging for a variety of reasons. First off, it's shocking how poorly it has been studied and how little time has gone into it. The other thing that may be at the heart of aging and disease is that many diseases are exacerbated with age, like cancer, Alzheimer's, type 2 diabetes. Given that, there may be common precursors that are interesting to go after, either from a therapeutic point of view or from a lifestyle point of view.
Even simple things like being overweight is a massive comorbidity for any of those things. Part of the challenge will be as a society, what we want to handle through the traditional healthcare model, which is basically a sick care model dealing with disease, or what we can do more broadly to actually get to longevity and never engage with the medical model in that way.
Andrew Scott
That's through your whole life. That's why I stress a longevity society, not an aging society. An aging society says, "What do we do with all these old people?" The real change is that the young can expect to become old. When you've only got a 10% chance of making it to 90, you shouldn't think in your 30s and 40s about what you can do now to be healthy in your 90s. But when there's a 50% chance of making it, you've got to start doing it.
We have this disease-focused model which just doesn't work as we get older, because chronic diseases have this common source. What is the X that affects all these later diseases? It could be aging, it could be obesity and GLP-1s, it could be exercise. That focuses on a really key issue: health. It strikes me as stunning that we don't say, "How do we maintain health?" We say, "How do we prevent disease?" It shows you the orientation of the system.
There's a quote by W.H. Jordan that I use in the book: "Health is the concept that medicine knows nothing about." I said this the other day to a cardiologist. He said, "No, health is just an incomplete diagnosis. Something happens and then I'm in."
Host
Can we speak to that? Something that you and many others have pointed out is this trend towards specialization in health care. At face value, that sounds pretty great—for anything I run into, there's a specialist who studied it much longer than the average doctor. As we're addressing the state of affairs, can you speak to that trend and how maybe it's not as compelling as you might think if we're trying to achieve longevity?
Andrew Scott
I don't want to criticize specialization. When we come to drug development, there are challenges because we're seeing a lot of drugs developed for very specific conditions where you can charge a lot, but you only affect a small number of people. It's brilliant that you affect those people, but what about the cross-cutting breakthroughs that we really need?
I think it's a consequence of disease specialization. As you start to have an older population, the real problem with specialization is you'll spend one morning with a cancer specialist, one morning with a cardiovascular specialist, one with a diabetic clinic. You get massive polypharmacy—multiple prescriptions of drugs where you have no idea how they interact because we haven't got clinical trials to prove it.
The other challenge is that as you get older, you get all these aging-related diseases. Fantastic if you can reduce the risk of cancer. But you've still got dementia, diabetes, and cardiovascular issues, all of which will lower the quality of your life. If you could do something early that affected multiple diseases, the whole is greater than the sum of its parts, which specialization is not going to give you.
Vijay Pande
Andrew hit it. The view that medicine starts with disease is part of the problem because it should start with health—to maintain health rather than to fix disease. We don't want our houses to be on fire, so we have smoke alarms. If we wait until the house is on fire, that's unfortunate and there's only so much you can do. We ask a lot from acute care, and they can do miraculous things. But it would be a lot healthier and a lot cheaper to address these issues early. That has its own challenges, and part of it is just not the way the system is built to work.
Andrew Scott
That is the problem. You're keeping people alive. You're not keeping them healthy. That's the real challenge. We're spectacularly successful in keeping people alive. But as we go beyond 70 into our 80s and 90s, we've slowed down the dying process, but not the aging process. That's a problem because you spend ever more money on sensible things, but you're not getting better health outcomes.
As an economist, there are tools where you can put dollar values on health gains and add them to GDP and say, "Here are the welfare gains we've got." Over the last decade, you've seen a really big slowdown in rich countries in terms of the health benefits they're getting. But health expenditure is still rising. In the US, health outcomes have been spectacularly bad compared to other countries.
Host
This is a good point to double click on the societal impact of that spend. We're in an election year with talk about inequality between middle class and upper class, that middle class wages have been flat. But if healthcare could have been kept at the same cost as 30 years ago, the middle class would have seen huge gains. Healthcare and its rising cost is eating up those gains. So it's not just about keeping us healthy, which would be great. It's about the health of the nation and the health of the economy.
Andrew Scott
There's another link as well, which I'm particularly keen on. If you could stop people in their 50s from having heart attacks, they can carry on working. That generates huge benefits in GDP and taxes. This is the key thing because you've got more and more older people. If you want them to work for longer, you've got to keep them healthy and productive for longer. You can't just say, "I've raised the social security age. Good luck."
Host
If we think about these incentives and how healthcare systems need to think about where they allocate resources, it's a very multivariate equation. I'd love for you to break down how these systems decide where to invest. I know there are different metrics, whether it's VSL or QALY—quality adjusted life year. But I also want to call out another metric from your book about action versus prevention. In 2020, total US healthcare expenditure was $4.1 trillion, around $12,500 per person. But of that, only around $363 was spent on prevention. That highlights exactly what both of you spoke to: we're not investing in prevention compared to action when something goes wrong. So how do these healthcare systems divvy up resources?
Andrew Scott
Globally, we've got the same problem: a pensions problem and a health problem. Within the details of the pension and health system in every country, it's wildly different. They're all going wrong in different ways. Broadly speaking, the Ministry of Finance hands a check to the Ministry of Health. The Ministry of Health has that stock of money and has to decide how to allocate it. It will look at some health measures. In the UK, one of the big targets is the waiting list for operations, which is a crazy metric because I can't see how that links into health measures very well.
There's also the medical concept of a QALY—a quality adjusted life year. If you have a treatment that saves a child's life and they can live to 80, you've saved 80 years, but you quality adjust the years for the level of health. You calculate that and set a price. In the UK, it's about 30,000 pounds, roughly $40,000. If a treatment comes in less than that price, it's worth it. If not, don't do it. In the US, budgets are much bigger and it's more of a commercial decision—how much you can pass on to the insurer. There's value-based pricing as well.
Most of the measures are very internal to the health system. That's a really big issue because with budgets under constraint, take the UK where they spend a lot more money but aren't getting better outcomes. You've got more older people who need operations—hip replacements, et cetera. You can't say no to them. So you haven't got the money to finance prevention, and you're stuck forever doing hip replacement operations.
The case for prevention is made on whether it will save money within the health system: "If I spend this now, will it reduce my operating costs now?" The problem is prevention takes time to come through. In the US health system, with multiple health providers, one person's expenditure could be someone else's benefit. In the UK, it's slightly easier because we have one health system. The Ministry of Finance pays for everything, so they can see the savings.
That's why I'm keen to say there's another gain to prevention: spillover benefits. In the UK, and I'm sure it's similar in the US, if you're 50 and have a heart attack, you're six times more likely to leave the labor market. Once you're out, it's very hard to get back in. If you can stop that person from leaving, you get knock-on effects in income, GDP, and revenue. That's not currently taken into account.
Vijay Pande
Very little time is discussed on prevention and nutrition. Those fields are complex and highly debated. There's the education part, which has huge room for improvement. But in the US, the big question is who's going to pay for it. Existing payers have to deal with the reality that people may switch payers every two or three years. Prevention is a long-term game.
There's a big push for value-based care, and I think there are new models for that, especially in areas like Medicare Advantage. But in the end, I think we're going to see high deductible plans and choice like ICRA that will allow consumers to be the ultimate payer. We are the ultimate payer in dollars, and we are obviously the ultimate payer in healthcare results. We care about value. I care about my children's health and my wife's health in a way that no insurance company would. That shift—who's going to pay and me choosing how my dollars are spent—could facilitate more prevention.
Andrew Scott
It's a really interesting point. Once you move away from the disease model, the health system becomes everything: the air you breathe, the real estate you live in, the food you buy. You're going to see it go retail in a very big way. Not everyone will spend and invest in health, but I think a logical consequence of prevention is that if health providers won't provide it sufficiently, other people will—whether through wearable devices or whatever. The health economy just starts to get even bigger.
Vijay Pande
Something a lot of people don't realize is that if you look at the determinants of health and especially mortality, genetics is a large part—30 or 40 percent. All of medicine is basically 10 percent. A large fraction, like 40 percent, is social determinants. If your spouse smokes, you'll either be smoking or have secondhand smoke. Your zip code predicts your health to a large degree. Those social determinants are a huge part, and addressing that should be part of healthcare. But right now, healthcare is really that 10 percent of providing disease-focused care. You're missing that 40 percent.
Andrew Scott
I completely agree. The socioeconomic determinants are huge. Behavior and environment explain the majority. One thing that's interesting is people are resistant to the idea that aging is malleable. But look at inequality: we found a way to speed up aging through socioeconomic determinants. That's proof positive that we can really affect how we age. It somehow just doesn't get into the consciousness.
Host
You gave examples in the book of some insurance companies incentivizing people who exercise or have healthy habits, or getting discounts on healthy food. I'm surprised we're not seeing that more. Maybe this is a good transition to talk about social implications and the major parts of society that need to be restructured, since some of this is inevitable. Things like the health system, the financial sector, taxes, career planning, drug design.
Andrew Scott
Let me reiterate the very simple idea of the book: for the first time ever, you can now expect to become old. You've got to make sure you're healthy and engaged for longer. You've got to invest more in your human capital. If you don't invest in your future, your future isn't very good. You run out of money, you run out of skills, you run out of purpose, you run out of health. But we never set up our institutions to say, "How does Andrew live a life to his 90 that remains healthy and engaged?" Nothing is untouched, including culture and psychology.
Where are the main things? The health system, huge. A shift to delivering health rather than treating disease. Work clearly has to change. In an early book, *The Hundred Year Life*, I talked about how we created a three-stage life in the 20th century: education, work, retirement. If you stretch that out to 90, it looks unappealing, pretty miserable.
For me, the simple notion is that longevity is about having more time. The question is, what do you want to do with that time? How do you distribute leisure across your life? In the 20th century, we fixed retirement age, lived longer, and took more and more leisure at the end of life. Governments around the world are saying that doesn't stack up. You're going to have to work for longer. I think we may take less leisure at the end of life, but we'll spread more leisure across life. We might start work later. We might take mid-career breaks. Your last job might be part-time, or you might go part-time in the middle.
Your career is going to have a lot more transition, some chosen by you, some forced upon you. That has big implications for different people. If you're a manual worker age 50, you can't carry on in a physical job. How do you transition into something different? If you're an investment banker working all those hours, you can't carry on beyond age 45 or 50. Do you take a break, retrain, and do something else? Wrapped into this is education, identity, and so many things.
Finance comes into it as well. The simple pension industry says accumulate money while you're working, run it down when you retire. But with a multi-stage life, accumulation becomes much more complicated. Finance has to do three things. One is create long-run saving products with a much more flexible pattern. Totally tie financing into health. The other big challenge is that in the 19th and 20th centuries, we developed a life insurance industry that paid out if you died young. The risk now is not that you die at the average, but that most people die above the average. There's a small chance of going above 100. One in five, one in six Brits are meant to live to 100 according to the government. How do you finance that? That living insurance—how do I provide you a steady stream of income in case you live a really long life—is a huge financial one.
Vijay Pande
There's a crisis that those who have anticipated see it, but everyday people don't think about it this way. The shift in the United States from pensions, which have defined payouts, to 401ks, which have defined contributions. In the context of living to 90 and maybe to 100, is your 401k set for you to live to 100? Is it built that way? What does that mean for when you stop working? Can you have a health span long enough to build a 401k to pay for your lifespan? These things are fundamental to us. By the time we're there, it's too late to make changes.
Andrew Scott
It's a really complicated problem. How long will I be able to work for? How long will I live for? How much money do I need when I retire? What's the rate of return going to be? Those answers will differ wildly for different people. It's impossible to be precise. Whatever plan you've got, you've got to have some flexibility. The key flexibility is investing in your human capital—your health and your skills. If you suddenly find you haven't got enough money, you can carry on working for longer. But if you haven't got the skills and haven't got the health, you've got a really big financial problem. The portfolio suddenly becomes not just my 401k. It is my health and my skills. Integrating those together is really important.
Host
You're calling out how this dynamic has completely flipped on its head. Before, it was how do I avoid dying early. Now it's what do I do if I live too long. That is a really interesting phenomenon. The statistics back it up in terms of probability, and we make decisions based on probability. On the end of people who might say, "I don't know if I want to live forever" or "Living to 100 doesn't sound so great," you mentioned throughout your book this bias people have around aging and the aging population, both on a personal level and on a societal level of requiring support from others who haven't sustained their health span. Can you speak to this further and talk about how we might need to update our priors based on these shifts?
There are definitely some cultural differences here. The UK and US are at one end of the spectrum. But in general, we underestimate the capacity of older people. That's ageism. And the trouble with that is it means we underestimate the capacity of our own later life.
I enjoy telling a story. I was teaching some Chinese MBA students this summer, and I was showing them the Chinese demographic data. These students were sort of late 20s, early 30s. And China's demographic change is truly striking. It's going from 1.4 billion people to 1 billion, with 45% of them being more than age 65. So I was showing the data and showing how in 35 years' time, there are all these people aged over 65. And I said to these Chinese MBA students, "How do you feel about it?" And they said, "It's a problem." I said, "Why?" They said, "But there's all these old people. They're going to get ill and they need a pension." And I said, "Well, who are these old people?" And they said, "What do you mean? They're old people." I said, "No, they're you."
It was remarkable how the penny dropped. Like, "Oh my goodness." When everyone hears about an aging society, it's all about old people. It's not about me. I'm going to be fine. I'm going to be fit and healthy. It was quite remarkable how we're negative about old people and we don't recognize that the big change is the young can now expect to become the old. I think there are all sorts of reasons for that negativity. But it's a fundamental problem because you underestimate the capacity of your own later years. You will underinvest in them. And so you lead to the very outcomes that you fear.
And then there are all the problems of ageism that come with any form of ism—if you assume that on the basis of a characteristic like age, this is what you're like, then you've got a problem. Because actually, the real thing about aging is diversity. People age really, really diversely. You can be 100 and literally running 100 meters—you can look at it on YouTube—or you can be 50 and in a wheelchair.
I think society has become very focused on chronological age. It's really interesting. In England, in 1601, we introduced the Elizabethan Poor Laws. It was to look after the poor and the old. But no one knew how old people were. There weren't birth certificates. There wasn't much numeracy. So until very recently, people didn't know when they were born or how old they were. The song "Happy Birthday" comes in the 1930s. It's just kind of pretty. So what the Poor Law said was, "Okay, old is someone who's lived a long time and can't look after themselves." The whole test was about: could you be functional?
Then bureaucracy comes along, and this is a nightmare, this test. Let's just say everyone over 65 is old. And that's what we do today. We say everyone over 65 is old. But of course, the problem with that chronological measure of age is it just measures how long you've lived. For me, there are two much more important measures. One is how many more years you can expect to live. I'm 59. At 59, I have to behave differently from my father and my grandfather at 59 because I can expect more years. And then, of course, the other thing is my biological age—how is my body aging and how am I dealing with it?
If you have that approach, you start to think, well, actually, being 59 doesn't really tell me much about Andrew. It's not that important a piece of information. But we zoom in on chronological age. We assume everyone over 65 is old. That is an enormous problem for firms, for instance. Whenever I see a presentation on the aging society story and a consultant comes on, I know the media are going to say, "Hey, you should invest in care homes and cruise ships because everyone over 65 is going to want a cruise ship or go to a care home." And you've lost the market completely, if that's the way you think.
Vijay Pande
I was just before this, actually, watching a video of Robert Marchand, the French 105-year-old cyclist. He unfortunately passed away at 109, but at 105, he was still cycling, still beating centenarian records. So to your point, age very much is a metric, but there are many others to pay attention to.
I feel like a lot of listeners at this point are convinced that longevity is more complex and important than they realized prior. So on a personal level, they're probably asking, "Okay, so what should I do?" Because I can impact this. Maybe starting out there, how would you both think about the 80-20? The big problem is both when we talk about diet and exercise. I think the first misconception is that there is a right diet for everybody and a right exercise plan. This is so individualized that we've seen lots of companies crop up to try to measure things that will allow you to know what the right diet is for you. So it starts with diet and exercise, but that's a lot easier said than done. It's really trying to figure out what is important for you.
From there, I think there are intriguing things on the horizon that are probably a little more bleeding edge. People take metformin, people take other supplements. I put that in the 20 or the 5%. I wouldn't start with that at all. I think if you've optimized your diet and you've optimized your exercise and you're still getting PRs in your 50s—either weights or cardio or whatever—and you want to go that last bit, that's one thing. But I think there's a lot of low-hanging fruit, especially for people who are fairly sedentary. I'm not a medical doctor, so I don't take anything that's not prescribed and proven, simply because I can't monitor my own health to know if it's working. I was saying this the other day to someone who takes lots of supplements, and they were shocked and said, "We'll miss you, Andrew." I don't take any of that, and I agree there's exciting stuff coming along.
Andrew Scott
It's always a disappointing thing, because people always want the easy answer. And there are some easy answers. It's exercise, diet, sleep, enjoyment, good company. At the moment, I would broadly say—although there's some latest evidence about high-intensity exercise and this way of sleeping and fasting—broadly speaking, we know what works. What's changed is our incentive to do it. I think that's the message you've got to drive home, not that there's some secret technique that's going to change everything.
We have done brilliantly inventing and innovating intervention techniques. We've now got to put the same effort into prevention. Data is going to be really important, and then I think we'll start seeing some more personalized medicine coming along. But none of that is going to happen quickly. So we're left with the stuff that really does make a big difference. If you look at the evidence on particularly healthy life expectancy, you're talking about another year or two for each of the things you do in terms of weight and exercise. That stacks up quite a lot.
Vijay Pande
I've seen myself and others—it's not overnight, but you can see gains in the first year and then they compound. And then it's about keeping it going. I think the maintaining is the hardest part—to avoid injury and to build that discipline.
We could also talk a little bit about the sci-fi stuff. Beyond the 80-20, this is like the 99.9 to 0.1. The sci-fi stuff is that there are just amazing new discoveries in the biology of cells and even organisms. The so-called Yamanaka factors—many people are searching for what really could be a fountain of youth. That is way off. I don't think you're going to be taking a pill like that anytime soon. But intermediate things: there are new pathways that correspond to pathways of exercise, and there are drugs in phase two for that. Even the GLP-1s—and there are pros and cons of them—may help you get started if you're obese. It's about coming up with a plan where this is not going to be a fad diet. This is going to be the rest of your life.
Andrew Scott
The GLP-1s are really interesting. I think we've still got some way to go to work out exactly what they're doing. But what is so interesting is, first of all, it looks like they give people a sense of agency and control so they can do other things. So it has a benefit for mental health. It's affecting multiple diseases. It's a bit like one of those biomarkers. And some of the effects seem to happen outside of an effect on obesity, which is exactly the sort of thing we need because the body is very complicated. Aging is not just one process. So there is unlikely to be just one pill we take that does everything.
I give the analogy with interest rates and the economy. The government changes interest rates to try and control the economy. It's not perfect, but it has a pretty big impact. So what's the equivalent? I think that's a really interesting example with the GLP-1s. And then, as you said, there will be lots of other stuff. I'm particularly taken by stem cells, where you can just regrow a liver. That's pretty sci-fi, but I think it's sort of pretty feasible to happen. Or drugs that treat arthritis. Wouldn't that be wonderful? I think that's the beginning of aging better, rather than here's something that's going to keep us alive till we're 150.
Host
If I'm taking anything away from both of you, it's that maybe we are at this interesting juncture where it really pays to think about this. I know that sounds really simplistic, but if we take your example, Andrew, of your family tree, that longevity that happened decade over decade was a little bit passive. It wasn't passive in terms of there being millions, if not billions, of people working toward those longevity gains. But your father or your grandfather weren't necessarily thinking, "Let me go test my VO2 max. Let me eat certain things." But now we do have more information than ever, especially in that 80%, as you said, Vijay. We're not even talking about the sci-fi stuff here. So there are very clear things that people have agency over.
Are there any other second- or third-order effects of this longevity revolution that you don't think we've necessarily touched on yet that people should be thinking about? For example, one that you mentioned in your book, Andrew, was menopause. It's something that a lot of people don't think about, but the health impact to 50% of humans is pretty substantial.
Andrew Scott
Menopause is a very interesting one because, of course, there's a huge impact on women's later life. Women tend to live longer but get into ill health before men. So a successful menopause is really important for later future health. It's an accelerated form of aging. And it's quite rare amongst animals. Humans are quite unusual in having a menopause. And of course, men's reproductive ability declines in the general form of age, but women's doesn't. So I think that's a really interesting area.
Our role models about how we live and what is old and what isn't old have been formed from centuries and millennia, and they radically need to change. The other thing I think it's important to stress is that we talk about there being more old people, but in many countries—the U.S. is an example—you used to have a pyramid that was lots of people at the bottom. Now it's more like a straight tower. So you've got age equality. Because of that, intergenerational connectivity becomes incredibly important. We design our institutions around a hierarchy, but we've got to get much better at that intergenerational mixing. How do you stop a hierarchy blocking progress for the young? How do you generally learn from one another and exploit that? That's going to be incredibly important.
Vijay Pande
There's a virtuous cycle and a vicious cycle. The vicious cycle is what we've been talking about—people are not paying attention to their health. They can't work, but they live long enough that they're very expensive and not contributing to GDP. The virtuous cycle is where people can maintain healthspan. They can continue to work. They can continue to contribute to their 401k. And instead of this being a crisis, it could be the greatest accomplishment of humanity—to allow people in their 60s, 70s, and 80s to have massive contributions like we'd only expect from people who are younger. That's an amazing future. And theoretically, we have all the elements. We just have to choose to do it. Mobilizing people to this problem, I think, is the imperative.
Host
If you think about it, the FDA was started before we even had access to penicillin or modern-day antibiotics. That speaks to the idea that these institutions, while they do many good things, are really, at least to some extent, a relic of the past. But that's exciting because there are clear wins.
Andrew Scott
I often quote Malthus. Back in 1799, he comes up with this very miserable thesis that says populations grow exponentially, our resources grow linearly, we've got too many people, and we're always going to have problems of illness, disease, famine, etc. That negativity is shared with the aging society story. The aging society story doesn't say we've got too many people; it says we're just living too long. We're outliving our ability to support this life, so we're going to get ill and we're going to have a pensions crisis.
It's interesting to go back. Malthus' writing on the world population was not even one billion. Now it's over eight. What Malthus got wrong is he didn't see innovation, invention, ingenuity, and new institutions that would come with the industrial revolution. They increased productivity. We invested in health and education, which further increased the quality of life. I think that's a metaphor for this aging society story. Where's the invention? Where's the ingenuity? Where's the innovation? Where are the new institutions? Because we can make this long life healthier and more productive. We just have to start doing it.
Host
All right, that is all for today. If you did make it this far, first of all, thank you. We put a lot of thought into each of these episodes—whether it's guests, the calendar Tetris, the cycles with our amazing editor Tommy, until the music is just right. So if you like what we've put together, consider dropping us a line at ratethispodcast.com slash A16Z. And let us know what your favorite episode is. It'll make my day, and I'm sure Tommy's too. We'll catch you on the flip side.